NeoCardial’s Principal Executives

Karl Groth, Ph.D. Dr. Groth has over 40 years of experience in the health care industry. Prior to joining NeoCardial Technologies, he was Chairman of Ascent Private Equity, which was the General Partner of the Ascent Medical Technology Fund, a $50 million venture capital fund focused on investments in private medical device, life science and biotechnology companies. Groth served as Chairman and CEO of Bioheart Inc. a publicly traded biotechnology company. He previously served as President and CEO of First Circle Medical Inc., a manufacturer and marketer of medical devices used in the treatment of patients with chronic intractable diseases, President and CEO of Browne Medical Systems, which he guided to a successful sale, and Executive Vice President and COO of InStent Inc.InStent Inc. went public in 1995 and was subsequently acquired by Medtronic in 1996. Groth also served as Director, International for Heart Technology, Inc. and Vice President of Marketing for Clarus Medical, both start-ups that were harvested with great success. He worked with Medtronic Inc. for a decade in a variety of business development and management positions, including product planning, product development, and long-range planning for the neuro division. He spent three years in Paris as Director of Non-Pacing Business for Europe, the Middle East and Africa. Prior to leaving Medtronic, he held the position of Director of Business Development. Dr. Groth served as Senior Scientist in the Department of Infectious Disease at the University of Minnesota. His research work focused on the development of antiviral drugs and vaccines. He has published over 30 peer-reviewed articles in professional journals. Dr. Groth received his B.S. from the State University of New York, his M.S. from New York University, and his Ph.D. from the University of Minnesota.

Peggy A. Farley has been involved in investment banking: corporate finance, venture capital and asset management, for over 40 years. In 1984, Ms. Farley developed AMAS Securities as a locus for direct and portfolio investment in the U.S. for US and non-US investors. In 1998, she founded Ascent, in 1999, acquired another firm, and by 2004, Ascent’s assets under management reached a level of $1 billion. In 2000, Ms. Farley founded Ascent Private Equity and during the period from 2000 to 2016, she engaged in venture capital, including the organization and co-management of the Ascent funds, as well as serving on the Boards of six medical device, biotech, and clinical research companies. She has a top-tier record of investment, has been well known for expertise in the IPO markets, and saw successful harvest of fund venture capital investments. From 1978 to 1984, she was with Morgan Stanley & Co. Incorporated, holding a key position in the International Group of its Corporate Finance Division. During her tenure with Morgan Stanley, she was advisor to the People’s Republic of China, working with Bank of China and other government ministries. She advised the country on approaching the principal capital markets to finance development programs. In addition, she conducted business with many of the top-ranking European and Japanese commercial banks and other foreign corporations, advising them on strategies for extending their reach into the U.S. markets, through both business combinations and the capital markets. Prior to joining Morgan Stanley, Ms. Farley served as consultant to U.S. corporations, including Avon, Ingersoll-Rand, Citibank, and Morgan Stanley. Her career in business began in the mid-1970’s in Citibank’s Athens-based Middle East and North Africa Regional Office, where she participated in the bank’s successful reach into those regional markets. She received her A.B. from Barnard College and completed her graduate work at Columbia University with High Honors.

Karl Groth, Ph.D.

Chief Executive Officer

Peggy A. Farley

Chief Financial Officer